[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Investigation Report on China's Recombinant Human Interferon ?2b Market, 2018-2022

January 2019 | 30 pages | ID: IC8EB94810AEN
China Research and Intelligence Co., Ltd.

US$ 2,200.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
DESCRIPTION

An interferon is a group of host-specific glycoproteins secreted by cells in response to virus infections or other factors. As a cytokine, it can defend against a wide variety of viruses by stimulating the synthesis of new effector proteins in interaction with the receptors on uninfected cells though it cannot directly kill or inhibit the viruses in cells. Besides, it can achieve immunoregulation and anti-cancer effects by enhancing the viability of lymphocytes, macrophages and natural killer cells.

In 1986, Intron A, the world's first Recombinant Human Interferon ?2b, was launched by Schering Plough that was later acquired by MSD, and approved by the FDA to be used for the treatment of chronic hepatitis B. In 1997, Tianjin Sinobioway Biomedicine Co., Ltd.'s Recombinant Human Interferon ?2b was approved to be sold in China, followed by the counterparts of Anhui Anke Biotechnology (Group) Co., Ltd., Zhejiang Beisheng Medicine Industry Hansheng Pharmaceutical Co., Ltd. and Schering-Plough that were approved in 1998, 1999 and 2007 respectively.

Recombinant Human Interferon ?2b has been approved by the China Food and Drug Administration to be sold in the dosage forms of freeze-dried powder injection, injection, suppository, cream (ointment), eye drops, etc. The main indications include acute and chronic viral hepatitis infections (hepatitis B and hepatitis C), condyloma acuminatum, hairy cell leukemia, etc. and vary among dosage forms.

CRI estimates that by the end of 2018, more than 90 million people in China are infected with hepatitis B virus and 8 million carry hepatitis C virus. With the increasing incidence of herpes, 80%-90% of the Chinese population are infected with herpes zoster virus, and 30% of the infected may develop chickenpox, and the rest 70% will be attacked by herpes zoster when they are weak. Furthermore, over 40% of married women in China are suffering from cervical erosion.

According to CRI's market research, the sales value of Recombinant Human Interferon ?2b showed an upward trend after the drug was launched in China, reaching about CNY 271 million in 2017. The injections, capsules and gels take up a large market share, with Shanghai Huaxin High Biotechnology Inc., Zhaoke Pharmaceutical (Hefei) Co. Ltd. and Schering-Plough as the top market players by sales value.

TOPICS COVERED:
  • Status of China's Recombinant Human Interferon ?2b market
  • Major manufacturers of Recombinant Human Interferon ?2b in China
  • Prices of Recombinant Human Interferon ?2b in China
  • Major factors influencing development of Recombinant Human Interferon ?2b in China
  • Prospect of China's Recombinant Human Interferon ?2b market from 2018 to 2022
1 RELEVANT CONCEPTS OF RECOMBINANT HUMAN INTERFERON ?2B

1.1 Indications for Recombinant Human Interferon ?2b
1.2 Development of Recombinant Human Interferon ?2b in China
1.3 Governmental Approval of Recombinant Human Interferon ?2b in China

2 SALES OF RECOMBINANT HUMAN INTERFERON ?2B IN CHINA, 2013-2017

2.1 Sales Value of Recombinant Human Interferon ?2b
  2.1.1 Overall Sales Value
  2.1.2 Sales Value by Region
2.2 Sales Volume of Recombinant Human Interferon ?2b
  2.2.1 Overall Sales Volume
  2.2.2 Sales Volume by Region
2.3 Sales of Recombinant Human Interferon ?2b by Dosage Form in China, 2013-2017
  2.3.1 Sales of Recombinant Human Interferon ?2b Gels
  2.3.2 Sales of Recombinant Human Interferon ?2b Sprays
  2.3.3 Sales of Recombinant Human Interferon ?2b Suppositories
  2.3.4 Sales of Recombinant Human Interferon ?2b Injections
  2.3.5 Sales of Recombinant Human Interferon ?2b Eye Drops
  2.3.6 Sales of Recombinant Human Interferon ?2b Capsules
  2.3.7 Sales of Recombinant Human Interferon ?2b Creams (Ointments)
  2.3.8 Sales of Recombinant Human Interferon ?2b Tablets

3 MAJOR MANUFACTURERS OF RECOMBINANT HUMAN INTERFERON ?2B IN CHINA, 2013-2017

3.1 Analysis on Market Share of Major Manufacturers of Recombinant Human Interferon ?2b
  3.1.1 Market Share by Sales Value
  3.1.2 Market Share by Sales Volume
3.2 Shanghai Huaxin High Biotechnology Inc.
3.3 Zhaoke Pharmaceutical (Hefei) Co. Ltd.
3.4 Schering-Plough
3.5 Beijing Kawin Technology Share-Holding Co., Ltd.
3.6 Tianjin Sinobioway Biomedicine Co., Ltd.

4 PRICES OF RECOMBINANT HUMAN INTERFERON ?2B IN CHINA, 2017-2018

4.1 Shanghai Huaxin High Biotechnology Inc. (Xinhuanuo)
4.2 Zhaoke Pharmaceutical (Hefei) Co. Ltd. (Yallaferon)
4.3 Schering-Plough (Intron A)
4.4 Beijing Kawin Technology Share-Holding Co., Ltd. (Kawin Yisheng)
4.5 Tianjin Sinobioway Biomedicine Co., Ltd. (Alfaron)

5 PROSPECT OF CHINA'S RECOMBINANT HUMAN INTERFERON ?2B MARKET, 2018-2022

5.1 Major Factors Influencing Development of Recombinant Human Interferon ?2b in China
5.2 Forecast on Market Size of Recombinant Human Interferon ?2b in China
5.3 Forecast on Market Trend of Recombinant Human Interferon ?2b in China

SELECTED CHARTS

Chart Governmental Approval of Recombinant Human Interferon ?2b in China
Chart Sales of Recombinant Human Interferon ?2b in China, 2013-2017
Chart Sales Value of Recombinant Human Interferon ?2b in Parts of China, 2013-2017
Chart Sales Volume of Recombinant Human Interferon ?2b in China, 2013-2017
Chart Sales Volume of Recombinant Human Interferon ?2b in Parts of China, 2013-2017
Chart Sales Value of Recombinant Human Interferon ?2b Gels in China, 2013-2017
Chart Sales Volume of Recombinant Human Interferon ?2b Gels in China, 2013-2017
Chart Sales Value of Recombinant Human Interferon ?2b Sprays in China, 2013-2017
Chart Sales Value of Recombinant Human Interferon ?2b Suppositories in China, 2013-2017
Chart Sales Value of Recombinant Human Interferon ?2b Injections in China, 2013-2017
Chart Sales Value of Recombinant Human Interferon ?2b Eye Drops in China, 2013-2017
Chart Sales Value of Recombinant Human Interferon ?2b Capsules in China, 2013-2017
Chart Sales Value of Recombinant Human Interferon ?2b Tablets in China, 2013-2017
Chart Market Share by Sales Value of Top 5 Manufacturers of Recombinant Human Interferon ?2b in China, 2013-2017
Chart Sales Value of Shanghai Huaxin High Biotechnology Inc.'s Recombinant Human Interferon ?2b, 2013-2017
Chart Sales Volume of Shanghai Huaxin High Biotechnology Inc.'s Recombinant Human Interferon ?2b, 2013-2017
Chart Sales Value of Zhaoke Pharmaceutical (Hefei) Co. Ltd.'s Recombinant Human Interferon ?2b, 2013-2017
Chart Sales Value of Schering-Plough's Recombinant Human Interferon ?2b, 2013-2017
Chart Sales Volume of Schering-Plough's Recombinant Human Interferon ?2b, 2013-2017
Chart Sales Value of Beijing Kawin Technology Share-Holding Co., Ltd.'s Recombinant Human Interferon ?2b, 2013-2017
Chart Prices of Shanghai Huaxin High Biotechnology Inc.'s Recombinant Human Interferon ?2b (Xinhuanuo) in Parts of China, 2017-2018
Chart Prices of Zhaoke Pharmaceutical (Hefei) Co. Ltd.'s Recombinant Human Interferon ?2b (Yallaferon) in Parts of China, 2017-2018
Chart Prices of Schering Plough's Recombinant Human Interferon ?2b (Intron A) in Parts of China, 2017-2018
Chart Forecast on Sales Value of Recombinant Human Interferon ?2b in China, 2018-2022


More Publications